As argued by Shi et al., the H. pylori negative modulation of the immune system and up-regulation of PD-L1 suggest that H. pylori may affect the efficacy of immunotherapy with PD-1/PD-L1 inhibitors in GC. Here, PDCD1 is linked to gastric cancer.